Edwards SAPIEN 3 TAVR Receives FDA Approval For Low-Risk Patients
Go back to Edwards SAPIEN 3 TAVR Receives FDA Approval For Low-Risk Patients| Edwards Lifesciences (NYSE: EW) | Delayed: 86.76 +0.58 (0.67%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $86.18 | 52 Week High | $166.87 | |||
| Open | $86.00 | 52 Week Low | $72.20 | |||
| Day High | $87.27 | P/E | 25.22 | |||
| Day Low | $85.00 | EPS | $3.44 | |||
| Volume | 1,553,795 | |||||
